Clinical study on the effects of nizatidine on gastric motility and cardiac autonomic function: Investigations using electrogastrography and spectral analysis of heart rate variability

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 8, 2004, Pages 427-435

  Tomokane, Yuko ^a   Nomura, Masahiro ^a,b   Kujime, Sae ^a   Noda, Yoshiko ^a   Kondo, Noriyasu ^a   Nakaya, Yutaka ^a   Ito, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Acinon ; CAS 76963 41 2; Gastric motility; H2 receptor antagonists; Nizatidine, effects on cardiac function, heart rate variability, QT interval

Indexed keywords

ACETYLCHOLINESTERASE; NIZATIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTROGASTROGRAPHY; ENZYME INHIBITION; FEMALE; FOOD INTAKE; HEART FUNCTION; HEART RATE VARIABILITY; HUMAN; LONG TERM EXPOSURE; MALE; QT DISPERSION; QT INTERVAL; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS;

EID: 4344652206     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296995     Document Type: Article

References (40)

1. 2-receptor antagonist, and its possible mechanism of action in dogs and rats. J. Pharmacol. Exp. Ther. 264, 152 (1993)
2. Kaneko, H., Mitsuma, T., Uchida, K. et al., Nizatidine accelerates gastric emptying of a solid meal in rats. Dig. Dis. Sci. 40, 2043 (1995)
3. Cloud, M. L., Enas, N., Offen, W. W., Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group. Clin. Pharmacol. Ther. 52, 307 (1992)
4. Lipsy, R. J., Fennerty, B., Fagan, T. C., Clinical review of histamine-2 receptor antagonists. Arch. Intern. Med. 150, 745 (1990)
5. Di Mario, F., Battaglia, G., Naccarato, R. et al., Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer - an 8-week randomized, double-blind multicentre study. Hepatogastroenterology 37, Suppl. 2, 62 (1990)
6. Hall, J. A., Washabau, R. J., Diagnosis and treatment of gastric motility disorders. Vet. Clin. North Am. Small Anim. Pract. 29, 377 (1999)
7. Okamoto, H., Nomura, M., Nakaya, Y. et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern. Med. 42, 655 (2003)
8. Katoh, K., Nomura, M., Iga, A. et al., Comparison of gastric peristalsis inhibition by scopolamine butylbromide and glucagon: evaluation by electrogastrography and analysis of heart rate variability. J. Gastroenterol. 38, 629 (2003)
9. Endo, J., Nomura, M., Morishita, S. et al., Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. J. Gastroenterol. 7, 888 (2002)
10. Appel, M. L., Berger, R. D., Saul, J. P. et al., Beat to beat variability in cardiovascular variables: Noise or music? J. Am. Coll. Cardiol. 14, 1139 (1989)
11. Malliani, A., Pagani, M., Lombardi, F. et al., Cardiovascular neural regulation explored in the frequency domain. Circulation 84, 482 (1991)
12. Van Ravenswaaij Arts, C. M. A., Kollee, L. A., Hopman, J. C. et al., Heart rate variability. Ann. Intern. Med. 118, 436 (1993)
13. Corinaldesi, R., Scarpignato, C., Galassi, A. et al., Effect of ranitidine and cimetidine on gastric emptying of a mixed meal in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 22, 498 (1984)
14. Ueki, S., Matsunaga, Y., Yoneta, T. et al., Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat. Arzneim.-Forsch./Drug Res. 49, 618 (1999)
15. Hansen, W. E., Bertl, S., The inhibition of acetylcholinesterase and pseudocholinesterase by cimetidine. Arzneim.-Forsch./Drug Res. 33, 161 (1983)
16. Galli, A., Mantovani, P., Pepeu, G., Effect of ranitidine on ileal myenteric plexus preparation and on acetyl- and butyrylcholinesterase. Biochem. Pharmacol. 33, 1845 (1984)
17. 2-receptor antagonist nizatidine. J. Pharmacobiodyn. 11, 767 (1988)
18. Hansen, W. E., Bertl, S., Inhibition of cholinesterases by ranitidine. Lancet 1 (8318), 235 (1983)
19. Scarpignato, C., Bertaccini, G., Zimbaro G. et al., Ranitidine delays gastric emptying of solids in man. Br. J. Clin. Pharmacol. 13, 252 (1982)
20. Lazzaroni, M., Porro, G. B., The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients. Hepatogastroenterology 36, 490 (1989)
21. Lanzon-Miller, S., Pounder, R. E., Chronos, N. A. et al., Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h. Gut 29, 1364 (1988)
22. Penaz, J., Mayer waves: History and methodology. Automedica 2, 135 (1978)
23. Madwed, J. B., Albrecht, P., Mark, R. G. et al., Low-frequency oscillation in arterial pressure and heart rate: a simple computer model. Am. J. Physiol. 256 (6 Pt2), H1573 (1989)
24. Pagani, M., Lombardi, F., Guzzetti, S. et al., Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ. Res. 59, 178 (1986)
25. Berger, R. D., Saul, J. P., Cohen, R. J., Transfer function analysis of autonomic regulation. I. Canine atrial rate response. Am. J. Physiol. 256, H142 (1989)
26. Hayano, J., Sakakibara, Y., Yamada, M. et al., Decreased magnitude of heart rate spectral components in coronary artery disease. Its relation to angiographic severity. Circulation 81, 1217 (1990)
27. Katona, P. G., Jih, F., Respiratory sinus arrhythmia: Non-invasive measure of parasympathetic cardiac control. J. Appl. Physiol. 39, 801 (1975)
28. Eckberg, D. L., Human sinus arrhythmia as an index of vagal cardiac outflow. J. Appl. Physiol. 54, 961 (1983)
29. Fouad, F. M., Tarazi, R. C., Ferrario, C. M. et al., Assessment of parasympathetic control of heart rate by a non-invasive method. Am. J. Physiol. 246 (6 Pt 2), H838 (1984)
30. Hayano, J., Sakakibara, Y., Yamada, A. et al., Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am. J. Cardiol. 67, 199 (1991)
31. Filipovic, M., Jeger, R., Probst, C. at al., Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. J. Am. Coll. Cardiol. 42, 1767 (2003)
32. Arai, Y., Saul, J. P., Albrecht, P. et al., Modulation of cardiac autonomic activity during immediately after exercise. Am. J. Physiol. 256, H132 (1989)
33. Lipsitz, L. A., Mietus, J., Moody, G. B. et al., Spectral chracteristics of heart rate variability before and during postural tilt: Relations to aging and risk of syncope. Circulation 81, 1803 (1990)
34. Breuer, H. W., Skyschally, A., Schulz, R. et al., Heart rate variability and circulating catecholamine concentrations during steady state exercise in healthy volunteers. Br. Heart J. 70, 144 (1993)
35. Casadei, B., Cochrane, S., Johnston, J. et al., Pitfalls in the interpretation of spectral analysis of the heart rate variability during exercise in humans. Acta. Physiol. Scand. 153, 125 (1995)
36. Hopf, H. B., Skyschally, A., Heusch, G. et al., Low-frequency spectral power of heart rate variability is not a specific marker of cardiac sympathetic modulation. Anesthesiology 82, 609 (1995)
37. Cowan, J. C., Yusoff, K., Moore, M. et al., Importance of lead selection in QT interval measurement. Am. J. Cardiol. 61, 83 (1988)
38. Ming, Z., Aronson, R., Nordin, C., Mechanism of current-induced early afterdepolarization in guinea pig ventricular myocytes. Am. J. Physiol. 267 (4 pt2), H1419 (1994)
39. Myerburg, R. J., Kessler, K. M., Mallon, S. M. et al., Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary artery spasm. N. Engl. J. Med. 326, 1451 (1992)
40. Wysowski, D. K., Corken, A., Gallo-Torres, H. et al., Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. 96, 1698 (2001)